Skip to main content
Avantor Inc (AVTR)
Drugs Health Care
Stock AI

Avantor Inc. Announces CFO Transition: R. Brent Jones to Depart by June 2026

Last updated: April 01, 2026
Taurigo

Avantor Inc. (NYSE: AVTR), a notable player in the life sciences and advanced technology sectors, has made headlines with the announcement of a key executive transition. The company's Executive Vice President and Chief Financial Officer (CFO), R. Brent Jones, will be leaving his position on or before June 24, 2026. This news comes as Avantor prepares for a critical leadership change while reaffirming its financial outlook for the year.

1. CFO Departure and Interim Leadership

In a move to ensure stability during this transition period, Avantor has initiated a search for its next CFO. To maintain continuity, Steve Eck, who currently serves as Senior Vice President and Chief Accounting Officer (CAO), will step in as interim CFO upon Jones' departure.

Eck brings a wealth of experience to the role. He has been with Avantor since 2019 and has played a pivotal role in overseeing financial reporting and internal controls within the organization. Before joining Avantor, Eck held prominent finance positions at notable companies such as CSS Industries, Fidelity National Information Systems, General Electric Company, and Deloitte & Touche LLP. His extensive background positions him well to navigate the company through this transition.

2. Financial Guidance Reaffirmed

Alongside the announcement of the CFO transition, Avantor has reaffirmed its fiscal 2026 financial guidance, which was initially communicated during the fourth quarter 2025 earnings call on February 11, 2026. This reaffirmation signals the company's confidence in its strategic direction and operational stability, despite the upcoming leadership change.

3. A Leader in Life Sciences

Avantor has established itself as a leading provider of mission-critical products and services in the life sciences and advanced technology sectors. The company works closely with its customers at every stage of the scientific journey, contributing to breakthroughs in medicine, healthcare, and technology. Avantor's extensive portfolio is utilized in a wide range of research, development, and production activities across more than 300,000 customer locations in 180 countries.

4. Conclusion

As Avantor prepares for this significant transition at the CFO level, the company appears committed to maintaining its strategic objectives and financial performance. The leadership of Steve Eck as interim CFO is expected to provide the necessary support during this period. Investors and stakeholders will be keenly watching the developments as Avantor continues to shape its future in the ever-evolving life sciences landscape.

You may also be interested in:
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.